NQO1 Induction and Radiation-Based Biodistribution Study of a New Quinoline Derivative Identified in a Screen of 6,8-Diiodoquinazolinone Sulfonamide Conjugates
Aiten M. Soliman, Mostafa M. Ghorab, Maureen Higgins, Albena T. Dinkova-Kostova, Mohamed Korany, Mohamed A. Amin, Mohammed A. Khedr, Tamer M. sakr
{"title":"NQO1 Induction and Radiation-Based Biodistribution Study of a New Quinoline Derivative Identified in a Screen of 6,8-Diiodoquinazolinone Sulfonamide Conjugates","authors":"Aiten M. Soliman, Mostafa M. Ghorab, Maureen Higgins, Albena T. Dinkova-Kostova, Mohamed Korany, Mohamed A. Amin, Mohammed A. Khedr, Tamer M. sakr","doi":"10.1016/j.ejmech.2025.117855","DOIUrl":null,"url":null,"abstract":"A series of quinazoline derivatives <strong>10–23</strong> incorporating benzenesulfonamide and various aliphatic, aromatic and heterocyclic acetamide tails were designed, synthesized, and <em>in vitro</em> evaluated for their ability to activate nuclear factor erythroid 2-related factor 2 (Nrf2) using its classical target NAD(P)H: quinone oxidoreductase 1 (NQO1) in Hepa1c1c7 murine hepatoma cells. Compounds <strong>13</strong> and <strong>20</strong> exhibited the highest potency among this series, with CD values 14 and 3 μM, respectively. The quinoline derivative <strong>20</strong> was subjected to radiolabeling. The radio-synthesized derivative was assessed for its biodistribution in normal and tumor-bearing animal models, where it displayed high <em>in vivo</em> stability and selectivity toward tumor cells. Molecular docking of <strong>20</strong> within the Nrf2-binding site of Kelch-like ECH-associated protein 1 (Keap1) predicted the highest binding affinity –<strong>8.76 Kcal/mol</strong> with the least RMSD value 1.01 Å. It showed a stable binding confirmed by RMSF compared to the co-crystallized ligand. This study identifies compound <strong>20</strong> as a promising antioxidant for continued optimization in redox-modulating research.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"61 1","pages":"117855"},"PeriodicalIF":6.0000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117855","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
A series of quinazoline derivatives 10–23 incorporating benzenesulfonamide and various aliphatic, aromatic and heterocyclic acetamide tails were designed, synthesized, and in vitro evaluated for their ability to activate nuclear factor erythroid 2-related factor 2 (Nrf2) using its classical target NAD(P)H: quinone oxidoreductase 1 (NQO1) in Hepa1c1c7 murine hepatoma cells. Compounds 13 and 20 exhibited the highest potency among this series, with CD values 14 and 3 μM, respectively. The quinoline derivative 20 was subjected to radiolabeling. The radio-synthesized derivative was assessed for its biodistribution in normal and tumor-bearing animal models, where it displayed high in vivo stability and selectivity toward tumor cells. Molecular docking of 20 within the Nrf2-binding site of Kelch-like ECH-associated protein 1 (Keap1) predicted the highest binding affinity –8.76 Kcal/mol with the least RMSD value 1.01 Å. It showed a stable binding confirmed by RMSF compared to the co-crystallized ligand. This study identifies compound 20 as a promising antioxidant for continued optimization in redox-modulating research.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.